Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookies. More details and information can be found in our Data Privacy Statement – please refer to this to adjust your settings for website analytics tracking (e.g. enable/disable). By closing this window you agree to our standard Terms of Use.

I'm ok with this

One-to-One Collaborations | PainSolve
;

Partnership &
Collaborations

One-to-One Collaborations

23andMe: Understanding the genetics of pain to identify new treatments for patients

Using DNA to understand why we react differently to pain.

In May 2017, we decided together with 23andMe, Inc. to conduct a joint study in 20,000 participants from the US in order to better understand genetic influences on pain. This study will be one of the largest of its kind to combine data on genetics and response to pain. The study will ask eligible genotyped customers to provide information about their experience with pain via online surveys. Participants will also be asked to self-administer the Cold Pressor Test to determine pain tolerance. The combined data set of survey answers and genetic information will provide insights into the different individual perceptions of pain, the different pathways that are involved, and how best to manage pain with more targeted treatments.

... Discover More

KU Leuven: Research collaboration for the development of novel non-opioid drug candidates

TRP ion channels: a novel, innovative and potentially pivotal target for non-opioid pain management

In April 2018, Grünenthal entered into a research collaboration with the Katholieke Universiteit (KU) Leuven's Centre for Drug Design and Discovery (CD3) and the Laboratory of Ion Channel Research (LICR). The partnership builds on lead compounds jointly developed by the CD3 and LICR, as well as on the extensive knowledge of Thomas Voets (LICR) and Joris Vriens (LICR), leading experts in the field of TRP ion channels, who have identified a novel, innovative and potentially pivotal target for non-opioid pain management.

"We are delighted to be part of this collaboration. It is a perfect example of an integrated approach that comprises the capabilities of the academic environment, early drug discovery centres and the pharmaceutical industry to deliver innovative solutions for unmet patient needs", Klaus-Dieter Langner, Chief Scientific Officer Grünenthal explains. "To leverage the latest approaches in pain research, Grünenthal is strongly committed to initiate close collaborations with the scientific community on early stage R&D projects."

Latest Updates

PainSpectrum – What, how, who?

Are you interested to learn more about how the PainSpectrum was developed and the reasoning behind it? Read our introductory article to the PainSpectrum here.

... Discover more

Psychosocial Factors in Profiling IBS Patients

Read our article on how relevant the neuro-visceral axis is for the expression of symptoms from which visceral pain conditions, like IBS, can originate.

... Discover more

Omics Approach to Identify Pain Pathways

Read our article about the steps we have taken to generate an integrated disease pathway map for pain which contains the major pathophysiological components.

... Discover more

Mechanisms of Placebo & Nocebo Responses in Clinical Trials

View Prof. Ulrike Bingel's (University Hospital Essen, Germany) third and final PainSolve webinar in her Placebo Effect series.

... Discover more
Like
 
Share

Share this with:

These are external links and will open in a new window